Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: A consensus report

Marcelo Cantarovich, Nigel W. Brown, Mary H.H. Ensom, Ashok Jain, Dirk R.J. Kuypers, Teun Van Gelder, J. Michael Tredger

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Assessing the value of mycophenolic acid (MPA) monitoring outside renal transplantation is hindered by the absence of any trial comparing fixed-dose and concentration-controlled therapy. However, in liver and thoracic transplantation particularly, clinical trials, observational studies with comparison groups, and case series have described MPA efficacy, exposure/efficacy relationships, pharmacokinetic variability, and clinical outcomes relating to plasma MPA concentrations. On the basis of this evidence, this report identifies MPA as an immunosuppressant for which the combination of variable disposition, efficacy, and adverse effects contributes to interindividual differences seemingly in excess of those optimal for a fixed-dosage mycophenolate regimen. Combined with experiences of MPA monitoring in other transplant indications, the data have been rationalized to define circumstances in which measurement of MPA concentrations can contribute to improved management of mycophenolate therapy in nonrenal transplant recipients.

Original languageEnglish (US)
Pages (from-to)65-77
Number of pages13
JournalTransplantation Reviews
Volume25
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Mycophenolic Acid
Pancreas
Thorax
Transplantation
Liver
Immunosuppressive Agents
Liver Transplantation
Kidney Transplantation
Observational Studies
Pharmacokinetics
Clinical Trials
Transplants
Therapeutics

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Cantarovich, M., Brown, N. W., Ensom, M. H. H., Jain, A., Kuypers, D. R. J., Gelder, T. V., & Tredger, J. M. (2011). Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: A consensus report. Transplantation Reviews, 25(2), 65-77. https://doi.org/10.1016/j.trre.2010.12.001
Cantarovich, Marcelo ; Brown, Nigel W. ; Ensom, Mary H.H. ; Jain, Ashok ; Kuypers, Dirk R.J. ; Gelder, Teun Van ; Tredger, J. Michael. / Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation : A consensus report. In: Transplantation Reviews. 2011 ; Vol. 25, No. 2. pp. 65-77.
@article{463ba105f9ed4d828c451a54fb07b588,
title = "Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: A consensus report",
abstract = "Assessing the value of mycophenolic acid (MPA) monitoring outside renal transplantation is hindered by the absence of any trial comparing fixed-dose and concentration-controlled therapy. However, in liver and thoracic transplantation particularly, clinical trials, observational studies with comparison groups, and case series have described MPA efficacy, exposure/efficacy relationships, pharmacokinetic variability, and clinical outcomes relating to plasma MPA concentrations. On the basis of this evidence, this report identifies MPA as an immunosuppressant for which the combination of variable disposition, efficacy, and adverse effects contributes to interindividual differences seemingly in excess of those optimal for a fixed-dosage mycophenolate regimen. Combined with experiences of MPA monitoring in other transplant indications, the data have been rationalized to define circumstances in which measurement of MPA concentrations can contribute to improved management of mycophenolate therapy in nonrenal transplant recipients.",
author = "Marcelo Cantarovich and Brown, {Nigel W.} and Ensom, {Mary H.H.} and Ashok Jain and Kuypers, {Dirk R.J.} and Gelder, {Teun Van} and Tredger, {J. Michael}",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.trre.2010.12.001",
language = "English (US)",
volume = "25",
pages = "65--77",
journal = "Transplantation Reviews",
issn = "0955-470X",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation : A consensus report. / Cantarovich, Marcelo; Brown, Nigel W.; Ensom, Mary H.H.; Jain, Ashok; Kuypers, Dirk R.J.; Gelder, Teun Van; Tredger, J. Michael.

In: Transplantation Reviews, Vol. 25, No. 2, 01.04.2011, p. 65-77.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation

T2 - A consensus report

AU - Cantarovich, Marcelo

AU - Brown, Nigel W.

AU - Ensom, Mary H.H.

AU - Jain, Ashok

AU - Kuypers, Dirk R.J.

AU - Gelder, Teun Van

AU - Tredger, J. Michael

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Assessing the value of mycophenolic acid (MPA) monitoring outside renal transplantation is hindered by the absence of any trial comparing fixed-dose and concentration-controlled therapy. However, in liver and thoracic transplantation particularly, clinical trials, observational studies with comparison groups, and case series have described MPA efficacy, exposure/efficacy relationships, pharmacokinetic variability, and clinical outcomes relating to plasma MPA concentrations. On the basis of this evidence, this report identifies MPA as an immunosuppressant for which the combination of variable disposition, efficacy, and adverse effects contributes to interindividual differences seemingly in excess of those optimal for a fixed-dosage mycophenolate regimen. Combined with experiences of MPA monitoring in other transplant indications, the data have been rationalized to define circumstances in which measurement of MPA concentrations can contribute to improved management of mycophenolate therapy in nonrenal transplant recipients.

AB - Assessing the value of mycophenolic acid (MPA) monitoring outside renal transplantation is hindered by the absence of any trial comparing fixed-dose and concentration-controlled therapy. However, in liver and thoracic transplantation particularly, clinical trials, observational studies with comparison groups, and case series have described MPA efficacy, exposure/efficacy relationships, pharmacokinetic variability, and clinical outcomes relating to plasma MPA concentrations. On the basis of this evidence, this report identifies MPA as an immunosuppressant for which the combination of variable disposition, efficacy, and adverse effects contributes to interindividual differences seemingly in excess of those optimal for a fixed-dosage mycophenolate regimen. Combined with experiences of MPA monitoring in other transplant indications, the data have been rationalized to define circumstances in which measurement of MPA concentrations can contribute to improved management of mycophenolate therapy in nonrenal transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=79953720823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953720823&partnerID=8YFLogxK

U2 - 10.1016/j.trre.2010.12.001

DO - 10.1016/j.trre.2010.12.001

M3 - Review article

C2 - 21454066

AN - SCOPUS:79953720823

VL - 25

SP - 65

EP - 77

JO - Transplantation Reviews

JF - Transplantation Reviews

SN - 0955-470X

IS - 2

ER -